Clinical Trial

Senicapoc in Alzheimer's Disease

Study acronym: Senicapoc
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 29, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-03-15; most recent amendment 2026-01-27.
Status change: Not Yet Recruiting → Recruiting 2022-03-23
Trial Details
NCT Number NCT04804241
Lead Sponsor University of California, Davis
Collaborators: Alzheimer's Drug Discovery Foundation, Alzheimer's Association, Biossil Inc.
Conditions Mild Cognitive Impairment, Alzheimer Disease
Enrollment 55 participants
Start Date 2022-03-18
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-01-29